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MRC Centre for Reproductive Health, Queen’s Medical Research Institute, University of Edinburgh, Edinburgh, UK
Remyelination is an example of central nervous system (CNS) regeneration, whereby
myelin is restored around demyelinated axons, re-establishing saltatory conduction
and trophic/metabolic support. In progressive multiple sclerosis, remyelination is limited
or fails altogether which is considered to contribute to axonal damage/loss and
consequent disability. Macrophages have critical roles in both CNS damage and
regeneration, such as remyelination. This diverse range in functions reflects the ability
of macrophages to acquire tissue microenvironment-specific activation states. This
activation is dynamically regulated during efficient regeneration, with a switch from
pro-inflammatory to inflammation-resolution/pro-regenerative phenotypes. Although,
some molecules and pathways have been implicated in the dynamic activation of
macrophages, such as NFκB, the cellular and molecular mechanisms underpinning
plasticity of macrophage activation are unclear. Identifying mechanisms regulating
macrophage activation to pro-regenerative phenotypes may lead to novel therapeutic
strategies to promote remyelination in multiple sclerosis.
Keywords: remyelination, microglia, macrophages, regeneration, inflammation, plasticity, multiple sclerosis,
myelin
INTRODUCTION
A prime example of regeneration in the central nervous system (CNS) is remyelination, whereby
following demyelination, myelin is regenerated around axons allowing recovery of saltatory
electrical impulse conduction and metabolic/trophic support. This involves recruitment and
proliferation of oligodendrocyte progenitor cells (OPCs) which subsequently need to survive and
differentiate into mature myelinating oligodendrocytes. Remyelination is limited or fails altogether
in the progressive phase of the autoimmune disease multiple sclerosis (MS), which is considered to
contribute to the axonal damage and loss that correlates to sensory, motor and cognitive decline.
Given that there are no approved therapies to drive remyelination in MS, identifying the cellular
and molecular drivers of remyelination is key in the development of novel therapeutics.
One of these cellular components includes cells of the innate immune system, such as
macrophages derived from CNS-endogenous microglia and monocyte-derived macrophages.
Macrophages are the first line of defense against infection and injury, involved in the phagocytosis
of apoptotic cells/debris, antigen presentation, secretion of growth/neurotrophic factors/cytokines,
and recruitment of other immune cell subsets. Although, initially implicated in tissue damage,
recent studies have expanded their roles to include tissue regeneration such as remyelination,
relating to their ability to phagocytose myelin debris and to secrete regenerative molecules. Indeed,
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minocycline-induced inhibition of microglia activation
significantly impairs remyelination (Li et al., 2005). The
diversity of macrophage function reflects acquisition of a diverse
spectrum of activation states in response to stimuli in their
microenvironment. The plasticity of this activation has been
demonstrated using models of demyelination showing that
microglia adopt different phenotypes during distinct stages
of myelin damage and regeneration (Olah et al., 2012; Voß
et al., 2012; Miron et al., 2013). Importantly, the phenotypic
profile of microglia during remyelination has been correlated
with functional changes, including phagocytosis of myelin
debris and apoptotic cells (Olah et al., 2012) and regulation
of oligodendrocyte progenitor cell responses (Miron et al.,
2013). These findings indicate that timed coordination of
particular macrophage phenotypes and functions are essential
for efficient remyelination, although the cues dictating their
activation and phenotypic switching remain poorly understood.
Gaining an understanding of these processes is imperative in
order to develop more effective therapeutic interventions for
neurodegenerative diseases like MS. This review will address
the roles of functionally distinct macrophage phenotypes during
regeneration (e.g., remyelination), the plasticity of this activation
and the molecular mechanisms involved.
ACTIVATION AND FUNCTIONS OF
MICROGLIA AND MACROPHAGES
DURING CNS REGENERATION
The extensive functions adopted by macrophages reflects their
response to their microenvironment, defined by interactions with
other cells, secreted products (such as cytokines), and signals
of injury (damage associated molecular patterns; DAMPS) or
infection (pathogen associated molecular patterns; PAMPS).
These microenvironment-specific functional macrophage
responses have been associated with marker expression
changes, termed “activation” phenotypes. Whereas earlier
studies categorized these activation phenotypes broadly
into 2 categories, with “M1” used as an umbrella term for
pro-inflammatory activation and “M2” used to describe anti-
inflammatory/immune-regulatory/wound-healing phenotypes,
recent studies have demonstrated that use of this terminology
can be misleading as various stimuli used to induce one of these
activation states can cause distinct gene expression changes (Xue
et al., 2014). Therefore, in order to avoid assumptions of gene
expression or function, and to achieve reproducible findings in
the macrophage field, Murray et al. (2014) proposed to define
macrophage activation by stimuli used, experimental conditions,
and a combination of markers. Therefore, we have adopted
this method to describe studies investigating microglia and
macrophage activation in CNS regeneration in this review.
Although, in vitro stimulation of macrophages may not
recapitulate the complexity of the CNS microenvironment, its
minimalistic approach has given useful insight into activation
state-associated gene expression and biochemical/functional
responses (Edwards et al., 2006). For example, in vitro
activation using interferon-gamma (IFNγ) and bacterial
peptide lipopolysaccharide (LPS), IFNγ and Fc receptor
(FcγR) stimulation, or interleukin-4 (IL-4) produce unique
gene, transcript and protein expression patterns, such that
only macrophages exposed to IFNγ express inducible nitric
oxide synthase (iNOS), whilst IL-4-treated macrophages are
the only group to express arginase-1 (Edwards et al., 2006).
In vitro experiments have identified potential molecular
mechanisms regulating effects of microglia on neural cell
progenitor responses. Co-culturing of microglia treated with
LPS (“Mi[LPS]”) blocked both neural progenitor cell (NPC) and
OPC differentiation via microglial secretion of pro inflammatory
tumor necrosis factor alpha (TNFα) (Butovsky et al., 2006).
Furthermore, although both Mi[IFNγ] and Mi[IL-4] co-cultures
promoted NPC and OPC differentiation, the effects of Mi[IL-4]
on oligodendrogenesis were much more pronounced, potentially
through secretion of high levels of insulin-like growth factor
1 (IGF-1) (Butovsky et al., 2006). Our own studies found that
microglia treated with IFNγ and LPS (Mi[IFNγ/LPS]) caused
expression of iNOS, co-stimulation molecule CD86, and Fc
receptor CD16/32 and was associated with in vitro induction
of OPC proliferation and migration (Miron et al., 2013).
Conversely, only treatment with IL-13 (Mi[IL13]) or IL-10
(Mi[IL10]) increased expression of arginase-1, mannose receptor
(CD206) and IL1Ra, with conditioned media driving OPC
survival under death-inducing conditions and differentiation
into mature oligodendrocytes, in part via secretion of activin-A
(Miron et al., 2013). Although, these experiments were carried
out under artificial environments, they revealed the importance
of microglia-derived factors in regulating progenitor responses
critical for CNS regeneration.
Recent studies have demonstrated that changes in
microglia/macrophage activation regulate their distinct
functions during CNS regeneration (summarized inTable 1). For
example, in a spinal cord injury model using electromechanical
displacement in which axonal regeneration is poor, mRNA
expression profiles of genes previously associated with
macrophage activation dynamically changed over time post
injury (Kigerl et al., 2009). Early time points were associated with
increased expression of iNOS, CD16/32, CD86, IFNγ, mannose
receptor and arginase-1, whereas expression of mannose receptor
and arginase-1 decreased at later time points. This suggested
a sustained pro-inflammatory phenotype over the long-term
post-injury associated with poor axonal regeneration. This was
not rescued by injection of axonal growth-promoting bone
marrow derived macrophages (treated in vitro with IL-4),
as subsequent to injection these cells changed phenotype to
mirror the activation phenotype in the lesion. However, direct
delivery of IL-4 into the CNS was able to overcome this, and
induce a pro-regenerative arginase-1+ macrophage phenotype
(Fenn et al., 2014). IL-4 injection also had a pro-regenerative
effect in the immune-mediated demyelination mouse model
experimental autoimmune encephalitis (EAE), where it increased
oligodendrogenesis in the spinal cord, suggesting potential
involvement of microglia/macrophages in remyelination. The
first definitive evidence of such involvement came from using a
lysolecithin (LPC)-induced focal model of demyelination in the
mouse spinal cord, showing that depletion of macrophages early
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TABLE 1 | Summary of microglia/macrophage phenotypic and functional characteristics during CNS injury and regeneration in vivo.
Experimental Model Microglia/Macrophage Markers Functional Outcome References
Spinal cord injury–electromechanical
displacement
iNOS, CD16/32, CD86, IFNy,
Arginase-1, Mannose Receptor
Poor axonal regeneration associated with
decreased Arginase-1 and Mannose Receptor
expression
Kigerl et al., 2009
Spinal cord injury–contusion Arginase-1, IL-1β, IL-4Rα Poor regeneration associated with lower
IL-4Rα expression on monocytes of aged mice
Fenn et al., 2014
CNS IL-4 injection promoted Arginase-1 in
macrophages, increased oligodendrogenesis
and improved regeneration
Experimental Autoimmune
Encephalomyelitis (EAE)
iNOS, Arginase-1 Increased iNOS associated with more severe
disease
Mikita et al., 2011
Increased Arginase-1+ macrophages
associated with milder disease and recovery of
symptoms
LPC-mediated demyelination of the
corpus callosum
3 dpl–iNOS, CD16/32, TNFα OPC proliferation Miron et al., 2013
10 dpl–Arginase-1, Mannose
Receptor, IGF-1
OPC differentiation into myelinating
oligodendrocytes
Cuprizone model of demyelination CX3CR1 CX3CR1 knockout mice displayed insufficient
myelin debris clearance and impaired
remyelination
Lampron et al., 2015
after injury using clodronate liposomes lead to a significant delay
in remyelination (Kotter et al., 2001). This pro-regenerative
role was later associated with phagocytosis of myelin debris,
normally inhibitory for remyelination,(Neumann et al., 2009;
Lampron et al., 2015) and recruitment of oligodendrocyte
progenitor cells (OPCs) to lesions (Kotter et al., 2005). Our
group subsequently showed that dynamic temporal regulation
of microglia/macrophage activation controls OPC responses
during remyelination (Miron et al., 2013; Figure 1). Using
LPC-induced focal demyelination in the mouse corpus callosum,
we investigated microglia/macrophage activation over time
during remyelination using markers previously used in studies
of regeneration of the CNS (Kigerl et al., 2009) or of skin
and muscle (Deonarine et al., 2007; Ruffell et al., 2009; Dayan
et al., 2011). We observed an iNOS+/CD16/32+/TNF-α+
microglia/macrophage population at 3 days post lesion, which
switched to an arginase-1+/IGF-1+/mannose receptor+
population at 10 days post lesion. Lineage tracing demonstrated
that this switch in activation took place in both microglia
and monocyte-derived macrophages. These phenotypic states
were associated with distinct functional roles, as depletion of
the iNOS+ population using gadolinium chloride (GdCl3)
(which competitively inhibits calcium signaling and has been
previously used to deplete pro-inflammatory macrophages
in vivo; Hardonk et al., 1992) reduced OPC proliferation,
whereas specific depletion of the arginase-1+ population
using mannosylated-clodronate liposomes reduced OPC
differentiation into mature oligodendrocytes and impaired
remyelination (Miron et al., 2013). The pro-remyelination
function of this later-arising microglia/macrophage population
was demonstrated to be mediated in part by the growth
factor activin-A (Miron et al., 2013). In addition, enhanced
remyelination in aged animals resulting from parabiotic
recruitment of young macrophages to LPC-induced spinal
cord lesions (Ruckh et al., 2012) was associated with an
increase in arginase-1+ and mannose-receptor+ cells, and not
iNOS+ or CD16/32+ microglia/macrophages, thus associating
enhanced densities of arginase-1+ macrophages with improved
remyelination (Miron et al., 2013). Interestingly, lineage tracing
demonstrated that only a small proportion of the arginase-1+
macrophages were derived from the young mouse, showing that
old microglia/macrophages adopted the regenerative phenotype
when exposed to the young macrophages (Miron et al., 2013).
Altogether, these studies have elucidated the dynamic regulation
of microglia/macrophages by the CNS microenvironment,
resulting in adoption of activation phenotypes that either impede
or promote regeneration. A key commonality between these
studies is that the temporal regulation of microglia/macrophage
activation, i.e., a turning off of “pro-inflammatory” responses
and switch to “pro-regenerative” function, is an essential aspect
of efficient regeneration.
It has therefore been postulated that an imbalance between
the pro-inflammatory and the regenerative macrophage response
may contribute to the failure of remyelination in MS. Post-
mortem tissue from MS patients has shown an abundance of
iNOS+ macrophages in chronic inactive lesions which show
poor remyelination, whereas mannose receptor+ macrophages
are increased only in actively remyelinating lesions (Miron
et al., 2013; Vogel et al., 2013). Interestingly, a population
of macrophages with an “intermediate” activation phenotype
characterized by expression of CD86, the chemokine CCL22 and
costimulatory molecule CD40 whilst being mannose receptor
negative predominate in “pre-active” normal appearing white
matter and remyelinating lesions, perhaps suggestive of a
population of macrophages caught mid-switch (Peferoen et al.,
2015). However, an intermediate CD40+ mannose receptor+
Frontiers in Cell and Developmental Biology | www.frontiersin.org 3 June 2016 | Volume 4 | Article 60
Lloyd and Miron Macrophage Activation and Function in Remyelination
FIGURE 1 | Microglia/macrophage functional phenotypes during CNS regeneration of myelin. Following focal demyelination of the adult mouse brain,
microglia/macrophages are activated to a pro-inflammatory (iNOS+ TNFα+ CD16/32+) phenotype which drives OPC proliferation but is not required for remyelination
to proceed. A switch to an ant-inflammatory/pro-regenerative phenotype (arginase-1+ mannose receptor+ IGF-1+) occurs which is needed for progenitors to
differentiate into mature oligodendrocytes and remyelination to subsequently take place.
phenotype is also abundant in chronic inactive lesions that
fail to remyelinate (Vogel et al., 2013) which may represent a
pathological block in macrophage phenotypic switching.
The balance between macrophage activation states is
predictive of disease severity in EAE. A favoring toward an
iNOS+ macrophage population is associated with a significantly
higher risk of relapsing EAE, and equilibrium in iNOS+ and
arginase-1+ macrophage populations predicts a milder disease
(Mikita et al., 2011). In addition, the switch to arginase-1+
macrophages is associated with attenuation of inflammation and
decreased disease severity (Ahn et al., 2012). Work from Mikita
et al. (2011) was one of the first to recognize the importance
of arginase-1+ macrophages in the recovery of EAE and that
promotion of the activation of such macrophage populations
may represent a novel therapeutic target for MS.Whereas relapse
occurrence was predicted by expression of iNOS in circulating
monocytes and suppression of arginase-1+ macrophages
and microglia, milder pathologies were characterized by low
numbers of activated monocytes in the brain stem. Furthermore,
therapeutic administration of IL-13- and IL-4-treated monocytes
suppressed EAE and decreased disease severity significantly,
accompanied by increased arginase-1 expression in the brain
stem. These studies suggested that promoting activation of
macrophages associated with arginase-1 expression may not only
attenuate a pro-inflammatory response, but also promote CNS
regeneration.
Overall, recent efforts to investigate the role of
microglia/macrophages in CNS regenerative processes, such
as remyelination, have identified the importance of temporal
control of activation from an initial pro-inflammatory response
to a pro-regenerative one. However, the cellular and molecular
mechanisms underpinning this switch in activation is unknown
but of vital importance in understanding pathological and
regenerative mechanisms in MS.
PLASTICITY OF MICROGLIAL AND
MACROPHAGE ACTIVATION DURING CNS
INJURY AND REGENERATION
Macrophages have long been recognized for their ability to
dynamically respond to stimuli in their microenvironment. The
concept of “macrophage plasticity” suggests that macrophage
activation state is not permanent, and that macrophages retain
the ability to adjust their activation in response to additional
stimuli in their microenvironment. This is an important concept
as it suggests that therapeutically targeting macrophages could
switch them from damaging to beneficial/regenerative activation
states. Some examples of where this could be applied include
aging or in MS, where pro-inflammatory microglia phenotypes
have been observed (Miron et al., 2013; Vogel et al., 2013; Grabert
et al., 2016). However, whether macrophages have the potential
to change their genetic, metabolic and functional signatures to
switch to an opposing role under these conditions remains to be
determined.
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The evidence for the ability of macrophages to undergo
a direct phenotypic switch is unclear. In vitro studies have
attempted to prove that such a switch can occur in macrophages,
identified by changes in gene and protein expression. LPS
treatment of microglia followed by treatment with IL-4 could
not reverse TNF-α production or promote IGF-1 production
(Butovsky et al., 2006). Whether this is due to a commitment
to an irreversible fate upon pro-inflammatory activation,
or to the sheer potency of stimuli like LPS that create
robust (and potentially physiologically irrelevant) inflammatory
responses remains uncertain. However, other experiments
using LPS-treated microglia subsequently treated with IL-4
have shown a significant decrease in the mRNA expression
of pro-inflammatory genes iNOS, Cox-2 and CD86, with
increased mRNA expression of mannose receptor and Arginase-
1 surpassing that observed with IL-4 treatment alone (Chhor
et al., 2013). The contradictory evidence for an in vitro activation
switch may be due to the differences in culture conditions,
treatment exposure times and end points. Conversely, it appears
that switching macrophages in vitro from anti-inflammatory
to pro-inflammatory phenotypes may be easier to achieve.
IL-4-primed microglia do not produce IL-10 in vitro, yet
addition of LPS produces a modest IL-10 response indicative of
plasticity (Edwards et al., 2006). Furthermore, IL-4-induced IGF-
1 production could also be blocked by LPS (Butovsky et al., 2006).
The question remains however, whether polarizing macrophages
and microglia in vitro is physiologically relevant, highlighting
the importance of using suitable ex vivo or in vivo models of
tissue microenvironment–specific inflammation to observe the
behavior and plasticity of these cells.
There is in vivo evidence for changes inmacrophage activation
following CNS injury. In a model of rodent spinal cord
injury through contusion, distinct populations of macrophages
are recruited to the lesion site (Kigerl et al., 2009; Shechter
et al., 2013). Recruitment is coordinated through two different
routes such that Ly6ChiCX3CR1lo macrophages associated with
expression of IL-1β, TNFα, and IL-12 are recruited through
the leptomeninges, and Ly6CloCX3CR1-GFPhi macrophages
expressing mannose receptor, IL-10 and TGF-β are recruited
via the choroid plexus (Shechter et al., 2013). This research
shows how the choroid plexus can prime macrophages to
become supportive for repair prior to exposure to the local
microenvironment at the lesion site, a previously unidentified
mechanism regulating macrophage diversity in vivo. Using a
focal lysolecithin-induced demyelination model in the corpus
callosum, our own studies also demonstrated a change in
microglia and monocyte-derived macrophage activation at the
onset of remyelination, from iNOS+ TNFα+ CD16/32+ to
arginase-1+ mannose receptor+ IGF-1+ phenotypes. These
studies demonstrate the diversity of macrophage activation
phenotypes following CNS injury and during regeneration;
however, the switching in activation of the same population of
cells remains to be unequivocally proven.
To gain a greater understanding of potential macrophage
plasticity during CNS regeneration (i.e., remyelination),
uncovering the cellular and molecular mechanisms that
underpin their activation is imperative. Furthermore, identifying
key regulators in the balance between the initiation and
resolution of inflammatory responses in macrophages may
uncover novel therapeutic targets for diseases like MS. Cross-talk
between signal transduction pathways involved in both the
initiation and resolution of inflammation by macrophages
during myelin injury and regeneration results in tightly regulated
responses, often by simultaneous activation and inhibition
of opposing activation states. For example, msh homeobox 3
(MSX3) promotes pro-repair responses in macrophages that lead
to oligodendrocyte survival in vitro and suppression of EAE in
vivo, whilst suppressing pro-inflammatory pathways (Yu et al.,
2015). MSX3 leads to activation of critical anti-inflammatory
mediators such as PPARγ and STAT6, both of which interact
in an inhibitory manner with pro-inflammatory pathways
including NFκB (Ohmori and Hamilton, 2000; Remels et al.,
2009). Indeed, the NFκB family of transcription factors is among
one of the most well characterized pro-inflammatory mediators.
Gene expression profiling of LPS-treated microglia in vitro have
shown that 72 out of 465 NFκB target genes analyzed were
significantly repressed or induced (Sharif et al., 2007). Moreover,
expression of CD40, a costimulatory molecule associated with
autoimmunity and MS, is upregulated in macrophages and
microglia following LPS treatment via activation of NFκB
(Qin et al., 2005). Its tight autoregulation ensures that its
rapid potent activation is controlled and resolved efficiently;
however dysregulation can lead to a prolonged inflammatory
and neurodegenerative response. Mutations in genes associated
with inhibition (Miterski et al., 2002) or constitutive activation
of NFκB (De Jager et al., 2009) have been found in MS patients
(Housley et al., 2016). Post mortem MS tissue shows strong
NFκB activity localized to macrophages near lesions (Gveric
et al., 1998), suggesting that a lack of regulation of NFκB may
contribute to the inflammation and pathology of the disease.
Therefore, blocking key inflammatory pathways may enable a
switch in macrophage phenotype and function, leading to the
resolution of inflammation and promotion of remyelination.
Other endogenous regulators of inflammation may also
provide clues as to how macrophage activation is regulated
during CNS injury and remyelination. One example is of PPARγ,
whose activation causes its translocation to the nucleus and
its binding to NFκB-specific binding sites, preventing NFκB
activation and the transcription of pro-inflammatory mediators
in a process called trans-repression (Paintlia et al., 2006; Szanto
and Nagy, 2008). PPARγ agonist administration in vivo can
promote functional recovery in a rodent SCI model (McTigue
et al., 2007) and neuroprotection when administered as a pre-
treatment before EAE induction (Polak et al., 2005), although it is
uncertain whether PPARγ agonists can promote recovery in these
models through non-macrophage cell types. However, it is known
that PPARγ expression is upregulated in microglia treated with
IL-4 in vitro (Paintlia et al., 2006). In vitro PPARγ activation with
specific agonists also decreases pro-inflammatory and increases
anti-inflammatory marker expression in macrophages infected
with the parasite t.Cruzi, a parasitic protozoan which produces
a potent pro-inflammatory activation phenotype in macrophages
(Penas et al., 2015). PPARγ activation also promotes the
transcription of anti-inflammatory molecules like IL-10 (Szanto
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and Nagy, 2008) and has therefore been identified as a potential
activation switch regulator for macrophages. Another example
is of substance P, which can promote activation or infiltration
of repair-associated macrophages in vivo and whose receptor
Neurokinin 1 is upregulated in IL-4-treated macrophages
(Marriott and Bost, 2000). Substance P administration at the
time of spinal cord contusion significantly decreases iNOS,
IL-6, and TNF-α mRNA expression whilst increasing IL-10
and Arginase-1 expression. This is associated with increased
mannose receptor+macrophages, conserved myelin sheaths and
improved functional recovery (Jiang et al., 2012). An additional
example is of 17β-estradiol, themost common estrogen produced
by the pre-menopausal ovary, which prevents NFκB activation in
macrophages by directly disrupting the microtubules associated
with NFκB nuclear translocation, preventing NFκB initiated
transcription of pro-inflammatory mediators (Ghisletti et al.,
2005) and promoting PPARγ activation (Kumar et al., 2004).
17β-estradiol administration in EAE decreases inflammatory
cell infiltration, delays the onset of symptoms and prevents
deterioration of neurological function (Feng et al., 2013). This
is associated with decreased protein levels of IL-1β, TNF-
α, IL-17, Rho kinase II, and increased IL-4 (Feng et al.,
2013). In vitro treatment of macrophages with 17β-estradiol
significantly decreases LPS-induced IL-1α, IL-6, and TNF-
α protein expression (Deshpande et al., 1997). In addition,
inhibition of an upstream activator of the NFκB pathway, Rho
kinase, with Fasudil modulates microglial activation, reduces
microglial infiltration to the spinal cord and improves functional
outcome in the SOD1 mutant mouse model of amyotrophic
lateral sclerosis (ALS) (Tonges et al., 2014). Fasudil also
decreases LPS-induced protein expression of TNF-α, IL-6, and
inflammatory chemokines CCL3, CCL5 and CXCl1 in microglial
cultures in vitro.
Whether the dynamics of macrophage activation is regulated
by a direct phenotypic switch or recruitment/expansion of
different macrophage populations during remyelination is
undetermined. Nonetheless, although endogenous inflammation
mediators are most likely acting upon a multitude of cell
types during CNS repair, it is evident that modulation of
key inflammatory pathways can not only alter the activation
of microglia and macrophages but can also have significant
effects on CNS injury and regeneration in various models
of injury. Therefore, finding ways to specifically promote a
switch in macrophage activation to pro- regenerative phenotypes
represents a novel therapeutic target for diseases like MS.
TARGETING MACROPHAGE ACTIVITY TO
PROMOTE REMYELINATION
Whilst immunomodulatory interventions aiming to dampen
initial myelin injury are highly successful in relapse-remitting
MS, there are currently no approved therapies to treat
the progressive phase of the disease during which failed
remyelination and neurodegeneration are prominent. Given the
implication of microglia and macrophages in remyelination,
global immunosuppressionmay be detrimental for remyelination
in progressive MS. For example, glatiramer acetate, a random
polymer of four amino acids of myelin basic protein, is an
immunomodulatory drug effective in treating relapse-remitting
MS but ineffective in progressive MS. This may be due to its
ability to inhibit microglial activity in MS patients (Ratchford
et al., 2012).
There are however some drugs in clinical trials specifically
aimed at enhancing remyelination. One of these is the anti-
LINGO-1 antibody; LINGO-1 is a negative regulator of
oligodendrocyte differentiation and myelination, and selective
blocking of LINGO-1 promotes remyelination and protects
axonal integrity in EAE (Mi et al., 2007). Another promising
drug in clinical trials for relapse-remitting and progressive
MS is Clemastine, a H1 histamine receptor antagonist. This
was identified via high-throughput in vitro screening of
compounds on cultured OPCs for pro-myelination capacity, as
measured by MBP staining surrounding concentric nanopillars
(Mei et al., 2014). Clemastine was also found to promote
OPC maturation in vitro and promote remyelination in
vivo in the LPC-induced demyelination mouse model (Mei
et al., 2014). Clemastine can also modulate macrophage
activation and function; for example, it inhibits ATP receptor
P2X7-dependant IL-1β release from LPS-primed human
macrophages in vitro (Norenberg et al., 2011) and increases
Arginase-1 and brain derived neurotrophic factor (BDNF)
expression levels in macrophages, conferring neuroprotection
in the SOD1 mutant mouse model (Apolloni et al., 2016).
Whether the Clemastine can promote remyelination in vivo
via modulation of macrophage activation remains to be
determined.
As of yet there are no MS therapies aimed specifically
at modulating microglial/macrophage function to promote
remyelination, although an experimental study emerged recently
which therapeutically targeted microglia and macrophages to
promote remyelination. Using a combination of the antifungal
drug Amphotericin B and macrophage colony stimulating factor
(M-CSF) to treat mice with LPC-induced demyelinated lesions
in the spinal cord caused a significant increase in macrophage
and microglia infiltration to the lesioned areas accompanied
by an increase in the scavenger marker MSR-1 on CD68+
activated macrophages and microglia, indicative of early myelin
debris clearance. This was associated with increased numbers of
OPCs and a higher proportion of remyelinated axons (Doring
et al., 2015), effects abrogated by clondronate liposome-mediated
depletion of peripheral monocytes.
Although, promising, the high toxicity and extensive
side effects associated with amphotericin B suggest its
translation to a mainstay prolonged treatment in MS is
unlikely. Together with the unproven efficacy of anti-
LINGO-1 antibody and Clemastine, this highlights the
need for development of novel strategies to promote
remyelination in MS. Whereas microglia and macrophages
have been targeted experimentally by immunomodulatory
drugs, Estradiol, NFκB modulators or PPARγ agonists,
potential effects on other cell types may render therapeutic
application difficult. Therefore, developing specifically targeted
therapeutics which effectively and specifically modulate
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macrophage activation to promote remyelination would be
ideal in minimizing off-target interactions and unwanted side
effects.
CONCLUSION
The functional diversity of CNS macrophages reflects their
ability to acquire tissue microenvironment-specific activation
phenotypes. During efficient CNS regeneration, such as
remyelination, such diversity is observed as a temporally
controlled switch in activation from pro-inflammatory to pro-
regenerative. However, the cellular and molecular mechanisms
underpinning this plasticity of macrophage activation remain
to be uncovered. This is critical for the development of novel
pro-remyelination strategies for MS that would center on the
manipulation of macrophage activation toward phenotypes that
are involved in inflammation resolution and are supportive of
remyelination.
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